Beta Bionics (NASDAQ:BBNX) Posts Earnings Results, Misses Estimates By $1.40 EPS

Beta Bionics (NASDAQ:BBNX) issued its quarterly earnings data on Tuesday. The company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($1.40), Zacks reports. Beta Bionics updated its FY 2025 guidance to EPS.

Beta Bionics Trading Up 2.5 %

Shares of NASDAQ:BBNX opened at $15.22 on Wednesday. Beta Bionics has a 1-year low of $13.64 and a 1-year high of $24.50.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Beta Bionics in a research note on Monday, February 24th. They issued a “buy” rating and a $25.00 price objective for the company. Robert W. Baird assumed coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price for the company. Lake Street Capital initiated coverage on Beta Bionics in a research report on Monday, February 24th. They issued a “buy” rating and a $30.00 price target on the stock. Bank of America started coverage on Beta Bionics in a research report on Monday, February 24th. They set a “buy” rating for the company. Finally, Baird R W upgraded Beta Bionics to a “hold” rating in a research note on Thursday, February 20th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.83.

Insider Activity at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger purchased 33,350 shares of the stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $17.00 per share, with a total value of $566,950.00. Following the acquisition, the insider now directly owns 59,019 shares of the company’s stock, valued at $1,003,323. This represents a 129.92 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the acquisition, the insider now directly owns 3,901,599 shares in the company, valued at $66,327,183. This trade represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.